SELLAS Life Sciences Group, Inc.SLSNASDAQ
LOADING
|||
Operating Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
-3.06%
↑ 74% above average
Average (39q)
-11.57%
Historical baseline
Range
High:79.72%
Low:-378.99%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -3.06% |
| Q2 2025 | -13.36% |
| Q1 2025 | 12.36% |
| Q4 2024 | 5.61% |
| Q3 2024 | 3.83% |
| Q2 2024 | 20.98% |
| Q1 2024 | -17.95% |
| Q4 2023 | 12.65% |
| Q3 2023 | -3.44% |
| Q2 2023 | 19.78% |
| Q1 2023 | -19.43% |
| Q4 2022 | -32.19% |
| Q3 2022 | 17.13% |
| Q2 2022 | -28.03% |
| Q1 2022 | -13.79% |
| Q4 2021 | 15.16% |
| Q3 2021 | -56.68% |
| Q2 2021 | -98.35% |
| Q1 2021 | 46.02% |
| Q4 2020 | 7.41% |
| Q3 2020 | -5.27% |
| Q2 2020 | -5.00% |
| Q1 2020 | 79.72% |
| Q4 2019 | -378.99% |
| Q3 2019 | -4.11% |
| Q2 2019 | 7.80% |
| Q1 2019 | 30.73% |
| Q4 2018 | -4.28% |
| Q3 2018 | 7.17% |
| Q2 2018 | -14.37% |
| Q1 2018 | 33.74% |
| Q4 2017 | -99.95% |
| Q3 2017 | 24.31% |
| Q2 2017 | -26.77% |
| Q1 2017 | 37.34% |
| Q4 2016 | -64.33% |
| Q3 2016 | 53.27% |
| Q2 2016 | -3.61% |
| Q1 2016 | -13.15% |
| Q4 2015 | 8.21% |